Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27196405 | 0.98 | HTR6 (0.55) | HTR6RETHTR2AIDO1CYP19A1 | |
| SCHEMBL428148 | 0.94 | HTR2A (0.53) | HTR6RETHTR2AIDO1 | |
| Oxalic Acid SCHEMBL5361082 | 0.90 | HTR6 (0.56) | HTR6RETHTR2A | |
| SCHEMBL62360 | 0.88 | HTR6 (0.59) | HTR6RETHTR2AIDO1 | |
| SCHEMBL61507 | 0.88 | HTR6 (0.59) | HTR6RETHTR2AIDO1 | |
| SCHEMBL29681415 | 0.88 | HTR6 (0.59) | HTR6RETHTR2AIDO1 | |
| SCHEMBL18440732 | 0.87 | CYP19A1 (0.55) | RETHTR2AIDO1CYP19A1TBXAS1 | |
| Hydrochloric Acid SCHEMBL15818880 | 0.86 | HTR6 (0.57) | HTR6RETHTR2AIDO1 | |
| SCHEMBL7898127 | 0.84 | IDO1 (0.52) | HTR6IDO1CYP19A1TBXAS1 | |
| SCHEMBL598590 | 0.81 | CYP19A1 (0.49) | IDO1CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0443588-B1 | Condensed thiazole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-06-23 | — | — | EP | claimed |
| EP-0352613-B1 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1994-04-20 | — | — | EP | claimed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | claimed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10807956-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-0395734-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0395734-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0325963-A1 | 1-Aminomethyl-1,2,3,4-tetrahydronaphthalenes and -indanes | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| EP-0325963-A1 | 1-Aminomethyl-1,2,3,4-tetrahydronaphthalenes and -indanes | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-11214542-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-10807956-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
| US-10597365-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | HTR6 2395/4885RET 1186/4885HTR2A 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.